MarketCap
X4 Pharmaceuticals XFOR
€ 2.89
-3.57%
Facebook
X
Telegram
X4 Pharmaceuticals Gesamtverbindlichkeiten | XFOR
Gesamtverbindlichkeiten Jährlich X4 Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 104 M | 124 M | 96.2 M | 81.5 M | 52.8 M | 50.1 M | 31.5 M | 14.4 M | 22.5 M | 64.2 M | 43.8 M | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 124 M | 14.4 M | 62.3 M |
Gesamtverbindlichkeiten Vierteljährlich X4 Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 92.9 M | 97.6 M | 102 M | 104 M | 102 M | 101 M | 107 M | 124 M | 119 M | 116 M | 111 M | 96.2 M | 106 M | 106 M | 72.7 M | 81.5 M | 72.7 M | 50.9 M | 49.9 M | 52.8 M | 51.8 M | 52.4 M | 54.1 M | 50.1 M | 43.4 M | 37.6 M | 34.9 M | 31.5 M | 30.4 M | 37.3 M | 33.1 M | 21.6 M | 18 M | 19.4 M | 20.8 M | 22.5 M | 22.5 M | 22.5 M | 22.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 124 M | 18 M | 63.9 M |
Gesamtverbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtverbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Trevena
TRVN
|
48.3 M | - | -46.58 % | $ 31.8 M |  USA |
 |
Immunovant
IMVT
|
104 M | $ 35.73 | 1.65 % | $ 6.52 B | USA |
 |
Virpax Pharmaceuticals
VRPX
|
2.47 M | - | -45.12 % | $ 2.85 M | USA |
 |
Oncorus
ONCR
|
85.1 M | - | -8.54 % | $ 3.19 M | USA |
 |
Y-mAbs Therapeutics
YMAB
|
27.9 M | - | - | $ 382 M | USA |
 |
Navidea Biopharmaceuticals
NAVB
|
12.5 M | - | -2.99 % | $ 2.47 M | USA |
 |
InMed Pharmaceuticals
INM
|
1.96 M | $ 15.56 | 13.57 % | $ 64.8 M |  Canada |
 |
Stealth BioTherapeutics Corp
MITO
|
95.5 M | - | - | $ 23.9 M | USA |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Satsuma Pharmaceuticals
STSA
|
8.12 M | - | -0.9 % | $ 36.5 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
8.95 M | $ 1.14 | -6.97 % | $ 97.2 M | USA |
 |
SpringWorks Therapeutics
SWTX
|
106 M | - | - | $ 3.48 B | USA |
 |
Metacrine
MTCR
|
15 M | - | - | $ 24.2 M | USA |
 |
Turning Point Therapeutics
TPTX
|
26.8 M | - | -0.13 % | $ 3.73 B | USA |
 |
Infinity Pharmaceuticals
INFI
|
61.2 M | - | -46.98 % | $ 3.57 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
15.8 M | - | 31.87 % | $ 1.61 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
Evelo Biosciences
EVLO
|
69.4 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Morphic Holding
MORF
|
25.5 M | - | - | $ 2.42 B | USA |
 |
Novan
NOVN
|
85.7 M | - | -24.84 % | $ 2.64 M | USA |
 |
Genocea Biosciences
GNCA
|
28.9 M | - | -15.0 % | $ 3.04 M | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
53.3 M | - | -9.21 % | $ 2.55 M | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
BELLUS Health
BLU
|
16.8 M | - | - | $ 2.47 B | Canada |
 |
bluebird bio
BLUE
|
492 M | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
218 M | - | - | $ 13.6 B | USA |
 |
IGM Biosciences
IGMS
|
218 M | - | - | $ 76.9 M | USA |
 |
Marinus Pharmaceuticals
MRNS
|
154 M | - | - | $ 29.6 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
441 K | - | - | $ 216 M | USA |
 |
CASI Pharmaceuticals
CASI
|
29.3 M | - | - | $ 35.4 M | USA |
 |
ContraFect Corporation
CFRX
|
32.5 M | - | -5.16 % | $ 5.39 M | USA |
 |
Sigilon Therapeutics
SGTX
|
48.1 M | - | - | $ 728 M | USA |
 |
Rubius Therapeutics
RUBY
|
7.94 M | - | -33.55 % | $ 7.81 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
TRACON Pharmaceuticals
TCON
|
15.4 M | - | -1.38 % | $ 46.8 M | USA |
 |
Mirati Therapeutics
MRTX
|
206 M | - | - | $ 3.3 B | USA |
 |
Revance Therapeutics
RVNC
|
630 M | - | - | $ 309 M | USA |
 |
Allogene Therapeutics
ALLO
|
123 M | $ 0.93 | -11.99 % | $ 205 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
3.08 M | - | -37.48 % | $ 476 K | USA |
 |
Epizyme
EPZM
|
289 M | - | - | $ 249 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | USA |
 |
ORIC Pharmaceuticals
ORIC
|
24.5 M | $ 8.9 | -3.63 % | $ 781 M | USA |
 |
Forward Pharma A/S
FWP
|
1.07 M | - | -0.75 % | $ 18.7 M |  Danmark |
 |
Orchard Therapeutics plc
ORTX
|
121 M | - | 1.02 % | $ 90.8 M |  Britain |
 |
La Jolla Pharmaceutical Company
LJPC
|
168 M | - | - | $ 154 M | USA |
 |
Oyster Point Pharma
OYST
|
123 M | - | - | $ 300 M | USA |
 |
Nabriva Therapeutics plc
NBRV
|
28.5 M | - | - | $ 4.55 M |  Irlanda |
 |
Intercept Pharmaceuticals
ICPT
|
461 M | - | - | $ 643 M | USA |
 |
NGM Biopharmaceuticals
NGM
|
20.2 M | - | - | $ 127 M | USA |